Company intelligence / Profile preview

CG Invites Co., Ltd.

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

CG Invites has achieved regulatory milestones including orphan drug designations for ivaltinostat in AML and hepatocellular carcinoma, completed multiple Phase 1 and Phase 2 studies, received expedited approval designations, and has one approved product—Acelex—for osteoarthritis in South Korea. Several programs are advancing through clinical stages up to Phase 3 for oncology indications.

Therapeutic areas: OncologyImmunologyHematologyOtherRheumatologyNeurologyInfectious Diseases
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

nilofabicin

Partnerships

AstraZeneca — strategic alliance agreement for joint R&D on novel antibiotics.Machaon Therapeutics — tech transfer agreement for ivaltinostat development in fibrotic diseases.

Beyond the preview

Go deeper on CG Invites Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG Invites Co., Ltd..

Explore the full profile